News
FENC
9.04
-2.22%
-0.21
Weekly Report: what happened at FENC last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at FENC last week (0408-0412)?
Weekly Report · 04/15 10:09
Weekly Report: what happened at FENC last week (0401-0405)?
Weekly Report · 04/08 10:12
Fennec Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/04 10:32
Fennec Pharmaceuticals Price Target Raised to $18.00/Share From $17.00 by HC Wainwright & Co.
Dow Jones · 04/04 10:32
Buy Rating Reaffirmed for Fennec Pharmaceuticals Following Strategic European Licensing Deal and Strong Financial Outlook
TipRanks · 04/04 10:26
HC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $18
Benzinga · 04/04 10:22
FENNEC PHARMACEUTICALS, INC. <FENC.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $18 FROM $17
Reuters · 04/04 10:06
Fennec Pharmaceuticals Reports Strong 2023 Growth
TipRanks · 04/01 18:37
Weekly Report: what happened at FENC last week (0325-0329)?
Weekly Report · 04/01 10:11
Fennec Pharmaceuticals: A Strong Buy on PEDMARK’s Success and Expansion Potential
TipRanks · 03/29 11:35
Weekly Report: what happened at FENC last week (0318-0322)?
Weekly Report · 03/25 10:13
Buy Rating for Fennec Pharmaceuticals Amidst Strong Pedmark Sales and Market Expansion Potential
TipRanks · 03/22 00:45
Fennec Pharmaceuticals Files SEC 8-K Report
TipRanks · 03/21 23:37
FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
Fennec Pharmaceuticals reported earnings per share of -10 cents. The company reported revenue of $9.74 million. This was 12.28% better than the analyst estimate for the company to report revenue of -8.7 million. The stock fell 2.7% after the report.
Investorplace · 03/21 18:52
Fennec Pharmaceuticals GAAP EPS of -$0.10 misses by $0.08
Fennec Pharmaceuticals Q4 GAAP EPS of -$0.10 misses by $0.08. Pro forma fourth quarter cash in excess of $55 million. The company's stock is up 2.7% in pre-market trading on Tuesday.
Seeking Alpha · 03/21 15:29
Fennec Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Fennec Pharmaceuticals Inc reports results for the quarter ended in December. Revenue rose 534.2% to $9.74 million from a year ago. The company reported a quarterly loss of $2.68 million. Fennec Pharmaceuticals reported an adjusted loss of 10 cents per share.
Reuters · 03/21 13:32
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/21 11:15
Fennec Pharmaceuticals’ Soaring Sales and New Deal
TipRanks · 03/21 10:37
Earnings Scheduled For March 21, 2024
Creative Realities is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. Welltower is likely to report earnings for its fourth quarter. Accenture is also projected to report before the bell. Other companies expected to be reporting before the Bell include Shoe Carnival, Y.M.C. And Y.T.
Benzinga · 03/21 10:15
More
Webull provides a variety of real-time FENC stock news. You can receive the latest news about Fennec Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About FENC
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company, which is focused on its product candidate PEDMARK. The Company sells its product through a field force, including regional pediatric oncology specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration (FDA) approved therapy indicates to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic and solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.